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ABSTRACT 
 
IN SILICO ANALYSIS OF MUTANT p53(R249S) ONCOGENICITY IN 
HEPATOCELLULAR CARCINOMA 
 
Guvanchmurad Ovezmuradov 
M.S. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Dr. Rengül Çetin-Atalay 
September, 2007  
      
     Oncogenic properties of mutant p53 proteins still stand as an ill-known subject, 
and the mechanism responsible for this phenomenon remains to be uncovered. This 
thesis aims to uncover the effect of p53 codon R249S ((AGG→AGT, arginine to 
serine) mutation on the development of hepatocellular carcinoma (HCC) through high 
throughput transcriptomics analysis using oligonucleotide arrays. We compared the 
expression profiles of HepG2 cells carrying wt and mutant p53(R249S). Microarray 
data analysis revealed a molecular signature consisting of 84 differentially regulated 
genes, showing that the expression of mutant p53(R249S) in HepG2 cells resulted in a 
distinct expression profile. Furthermore, mapping these significant differentially-
expressed genes to the p53 interaction network revealed a putative interaction 
network representing functional outcomes of p53(R249S) expression in the context of 
diverse molecular interactions. Our results clearly demonstrated that several 
Hepatocyte Nuclear Factors (HNF1A, HNF4A and HNF6) could play an essential role 
in mediating mutant p53 oncogenic activity in HCC, as the key molecules of the gene 
network.  
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ÖZET 
 
HEPATOSELLÜLER KARSINOMADAKİ  
MUTANT p53(R249S) ONCOJENİSİTENİN İN SİLİCO ANALİZİ  
 
Guvanchmurad Ovezmuradov 
Moleküler Biyoloji ve Genetik, Yüksek Lisans 
Tez Yöneticisi: Yard. Doç. Dr. Rengül Çetin-Atalay 
Eylül, 2007 
 
     Mutant p53 proteinlerinin onkojenik özellikleri hala az bilinenen bir konudur ve bu 
olguyu sağlayan mekanizma hala çözülmüş değildir. Bu tezin amacı, oligonukleotid 
dizinlerinin kullanıldığı geniş ölçekli transkriptomik analizini yaparak, p53’ün 249. 
kodon (AGG→AGT, arjininden serine) mutasyonunun hepatosellüler karsinomaya 
(HCC) olan etkisini ortaya çıkarmak. Wild-type ve mutant p53(R249S) taşıyan 
HepG2 hücrelerinin ifade şekli karşılaştırıldı. Mikrodizin veri analizi sonucu ifadesi 
değişen 84 genden oluşan ve bir “moleküler imza” niteliğinı taşıyan bir ifade 
değişikliği açığa çıkarılarak, mutant p53(R249S) ifadesinin Hep G2 hücrelerinde 
tamamen ayrı bir gen ifade şekline sebep olduğu gösterildi. Ayrıca, bu 84 genin p53 
etkileşim ağına eşlestirilmesi sonucu p53(R249S) ifadesinin işlevsel sonuçlarını  
degişik moleküler etkileşimler bağlamında açıklayan varsayımlı bir etkileşim ağı 
ortaya cıkarıldı. Bu çalışmayla elde edilen sonuçlarla, birkaç Hepatocyte Nuclear 
Factor’ün  (HNF1A, HNF4A and HF6) ilgili gen ağının kilit molekülleri olarak 
mutant p53’ün HCC’deki onkojenik aktivitesinin sağlanmasında önemli roller 
üstleniyor olabildikleri gösterildi.  
 
Anahtar sözcükler: p53, hepatosellüler karsinoma, mikrodizin, gen ağı, 
biyoenformatik. 
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CHAPTER 1: INTRODUCTION 
 
1.1. p53: A Two-faced Cancer Gene 
1.1.1. p53 History      
     Tumor protein 53, hereafter to be referred as p53, is one of the most extensively studied 
genes in molecular biology. Since its discovery in 1979, there has been a remarkable change 
in depicting the role of p53 in tumorigenesis [1] [2] [Fig. 1.1]. Intriguingly, p53 was initially 
described as an oncogene because of its higher expression in tumor cells, profound 
promoting effect on immortalizing certain cell types and ability to assist cellular 
transformation [1]. Surprisingly, 10 years after the identification of p53, it was realized that 
previous studies unknowingly utilized mutant forms of p53, and therefore all corresponding 
findings were related to mutant protein [3]. Moreover subsequent intensive studies revealed 
that the actual wild-type p53 gene is a tumor-suppressor gene, making it one of the most 
intensively studied human cancer genes [1].  
 
Figure 1.1: Diagrammatic illustration of the history of p53 functions since its discovery in 1979. (Hussain SP 
and Harris CC, 2006) [2] 
     Despite the fact that the most studies on p53 have concentrated on addressing the tumor 
suppressor functions of wild-type p53, the research on mutant p53 as an oncogenic protein 
still goes on yielding significant results [1]. 
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1.1.2. p53 as a Guardian of the Genome 
     Recent advancements in molecular biology have revealed that close regulation of 
biological processes on cellular level is indispensable for life [4]. Any abnormal molecular 
condition is sensed by complex surveillance mechanisms and cell fate decision is made 
resulting in its rectification, to cell death, or to disease such as in cancer if this is not possible 
[4]. p53 plays an essential role as the master regulator of these events, and thus has been 
widely regarded as “the guardian of genome” [5]. Accordingly, TP53, the gene encoding 
p53, is considered to be one of the most essential genes in preventing cancer, and has been 
investigated intensively for more than twenty years [3]. These growing studies resulted in 
recognition of tumor suppressor p53 as a key element of the cell’s antiproliferation 
machinery, accomplishing its effect by inducing either cell cycle arrest or apoptosis in 
response to various stress conditions [3]. These observations underscore the importance of 
p53 in tumor suppression and explain why p53 is prominent as the most frequently mutated 
gene (observed in half of all cancers) among human cancer genes [3]. Such a high frequency 
of mutations suggests a strong selective pressure for disruption of normal p53 activity in the 
process of tumorigenesis [6]. Accordingly, it’s obvious that the disruption of wild-type p53 
activity is vitally important for tumorigenesis [7]. Interestingly, beside of being such 
common as somatic mutations in human malignancies, alterations of the TP53 gene are also 
prominent as germline mutations in some cancer-prone families with Li-Fraumeni syndrome 
[8].  
     On the other hand, recent findings in this area revealed a broad spectrum of wild-type p53 
activities including maintaining the genomic integrity (as a “Guardian of the genome”), 
transcription, cell cycle, apoptosis, senescence, DNA repair and development [2] [Fig. 1.1].  
These findings clearly indicate that wild-type p53 acts as a key cell-growth regulator and 
tumor suppressor protein [9] at the crossroads of multiple cell signalling pathways.  
1.1.3. Is Mutant p53 an Oncogenic Protein? 
     Efforts to decipher the oncogenic properties of mutant p53 proteins have yielded a 
considerable amount of elucidative results. The evidences supporting the idea of classifying 
mutant p53 as an oncogenic protein can be summarized in three parts: 
     1. High frequency of missense mutations: Overwhelming majority (74%) of p53 
mutations are missense mutations, resulting in full-length, though mutant, proteins [10]. This 
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frequency of missense mutations is noticeably much higher when compared to other tumor 
suppressor genes [10], as the mutations striking other tumor suppressor genes (like APC, 
ATM and BRACA) in the majority of cases are reading-frame shifts or nonsense mutations 
[11] [12] [Fig. 1.2]. As a consequence, while mutations of other tumor suppressor genes 
result in truncated proteins, often degraded rapidly in cell, p53 mutations result in slightly 
altered, albeit stable proteins [11] [12]. This striking observation led scientists to the 
inescapable conclusion that mutant p53 proteins contribute to tumorigenesis by conferring 
selective advantage to cells harbouring them [10], as these cells can benefit from the 
presence of a slightly altered p53 protein rather than from its complete absence [11]. 
Consequently, it can be deduced that mutations in the p53 gene gain oncogenic functions to 
its protein products (oncogenic “Gain of function”, GOF), besides destroying the tumor 
suppressor function of the wild-type protein [13].    
 
Figure 1.2: High frequency of missense mutations affecting p53 compared to other tumor suppressors. 
(Weinberg RA, 2006) [11] 
     2. Accumulation in tumor cells: Mutations of p53 result to the accumulation of high levels 
of mutant p53 in tumor cells [12]. This happens because only mutant p53, but not its wild-
type form is stable in the nucleus of tumor cells [12] Observation that the levels of p53 
protein in tumour cells are significantly higher than p53 levels in normal cells [1] strongly 
suggests that these mutant proteins are selectively overexpressed because of their vital 
oncogenic role in tumor progression [13].    
     3. Oncogenic activity in tumor cells: Since its early discovery, the research on p53 has 
revealed a solid knowledge that mutant p53 proteins have oncogenic properties which 
contribute to the establishment of malignant phenotype [14]. Early studies identified that 
consequences of expressing mutant p53 is not equivalent to the simple loss of wild-type p53: 
mutant p53 expression is capable of immortalizing certain cell types and of cooperating with 
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other oncogenes in cellular transformation [1] [7]. In recent years, a growing number of 
studies have demonstrated both in-vitro [15] [16] and in-vivo [17] [18] that expression of a 
mutant p53 can generate a broad variety of new oncogenic functions which enhance 
oncogenic potential of cells that express these proteins [14] [7] [Fig. 1.3]. Most remarkable 
are in-vivo studies [17] [18] utilizing mouse models in which mutant p53 expression is 
strongly correlated with a change in tumor spectrum in addition to enhancement of metastatic 
potential compared to p53-null mice [7]. All of these sophisticated studies have provided a 
compelling evidence of mutant p53 oncogenic activity in tumor cells [15].     
     Taking in account all of the evidences provided above, it’s obvious that p53 doesn’t fully 
obey the Knudson’s two-hit model [19] of how tumor suppressor genes should operate [11]. 
Actually, since p53 is simultaneously both a tumor suppressor gene and an oncogene, it can 
truthfully be regarded as a two-faced cancer gene [14] [Fig. 1.3].  
 
Figure 1.3: p53: a two-faced cancer gene. (Kastan MB and Berkovich E, 2007) [14] 
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1.1.4. Hot Spot Mutations of p53 
     Noticeably, overwhelming majority (>90%) of missense mutations in p53 affect the 
sequence-specific DNA-binding domain (DBD) of the protein, whereas more than 40% of all 
missense mutations alter codons R175, G248, R248, R249, R273 and R282 located within 
this domain [20] [Fig. 1.3]. Mutations in these six codons are the subjects in the majority of 
p53 studies and are commonly referred as hot-spot p53 mutations [21].     
 
Figure 1.4: Distribution of p53 mutations. (Weinberg RA, 2006) [11] 
1.1.5. Role of p53 Mutations in Tumorigenesis 
     Though extensive studies in this area, the exact mechanism responsible for mutant p53 
contribution to tumorigenesis is not yet well defined [3]. The most promising model implies 
a paradigm of triple oncogenic effect caused by p53 mutations: (a) loss of function effect, 
where the tumor suppressor function of p53 is disrupted  (b);  dominant negative effect, 
where wild-type p53 function is inactivated as result of hetero-oligomeric complex formation 
between wild-type and mutant p53 proteins, and (c) gain of function (dominant-positive) 
effect, where mutant p53 acquires novel oncogenic functions not seen in wild-type p53 that 
are independent of complex formation with wild-type p53 and therefore may occur in the 
absence of second (wild-type) p53 allele [3] [13] [22] [Fig. 1.4].  
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Figure 1.5: Proposed mechanisms for the role of p53 mutations in tumorigenesis. 
(Cadwell C and Zambetti GP, 2001) [3] 
     The gain of function hypothesis for mutant p53 has been tested in cells devoid of 
endogenous p53 [18] [23]. Since there was no endogenous wild-type p53 activity for the 
mutant p53 to interfere with, it was concluded that mutant p53 must have been directly 
causing the stimulation of unregulated cell growth [13]. Last but not least, mutant p53 gain of 
function can also be linked to physical interaction of mutant p53 with other p53 family 
members, p73 and p63 [13]. Although wild-type p53 shows no obvious ability to bind p63 or 
p73, mutation can provide “gain of this ability” [7]. Indeed, recent studies have confirmed 
these interactions for a subset of p53 mutants and demonstrated subsequent functional 
outcomes: mutant p53 binding to its sibling proteins results in their inhibition [7] [21].     
1.1.6. Mechanisms of Transcriptional Regulation by Mutant p53 
     Ability to regulate gene expression and modulate the transcriptome of the mutant cell is 
considered as one of the major mechanisms underlying mutant p53 GOF [1] [24]. Indeed, the 
series of studies have demonstrated the ability of mutant p53 to turn on and off specific sets 
of genes through acting as a transcription factor [25]. Noticeably, these genes are not 
regulated by wild-type p53 and none of them contain wild-type p53 DNA biding consensus 
site [3] [26]. Moreover, the repertoire of mutant p53-responsive genes is significantly distinct 
from that of wild-type p53 [26]. This implies that the alteration in target gene specificity is 
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what really responsible for mutant p53 GOF [26]. Given this, the meaningful question arises: 
How the specificity of mutant p53-mediated transcriptional regulation is achieved? [26]. As a 
consequence, it remains a challenging task to elucidate at the molecular level the mode of 
this transcriptional regulation [1] [24].  
     Currently, it seems to be a consensus on two molecular scenarios explaining function of 
mutant p53 as an oncogenic transcription factor [25] [Fig. 1.5]. While the first model 
depends on altered protein-DNA interactions of p53, the second one relies on its altered 
protein-protein interactions.     
     First model, based on “direct binding” [27], presumes direct binding of mutant p53 to the 
target DNA sequences, through yet unknown mechanisms which involve intrinsic DNA 
binding activities of mutant p53 proteins themselves [25]. The issue of sequence-specific 
binding is still under debate: since different mutant p53-responsive promoters show no 
sequence homology, the linear DNA sequence motif serving as a mutant p53-specific binding 
site couldn’t have been defined so far [1] [26].  
     According to the second model, based on “passive targeting” [27], mutant p53 can be 
recruited to its promoters in a specific manner indirectly and independently from the 
presence of canonical p53 binding site [1] [28] [26] [25]. This targeting is possible through 
physical interaction of mutant p53 with other sequence-specific transcription factors, such as 
Ets-1, SP-1 and NF-Y [1] [28]. The fact that both mutant p53 and these transcription factors 
are direct transcriptional regulators of the set of common genes further supports this notion 
[26] [27]. Consequently, being a member of a transcriptional protein complex enables 
tethering of mutant p53 to its promoter regions [25].  
 
Figure 1.6: Models for mutant p53 transcriptional activity. (a) Mutant p53 binds the regulatory regions of its 
target genes through a specific and yet unknown DNA-binding consensus sequence; (b) mutant p53 interacts 
with a specific transcription factor that drives its gene target specificity. (Strano S et al, 2007) [25] 
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     From the structural view, the two models can be explained through “cause-result” 
relationship. The structural changes resulting as response to mutation, determine three 
important properties of mutant p53 protein: (i) its folding state; (ii) its affinity for a range of 
target promoters; (iii) its affinity to others proteins [29]. While the second one explains the 
alteration of target DNA selectivity, the third one sheds light on the variation in protein 
interactions. Therefore, it is apparent that while the change in p53’s affinity to DNA 
sequences can clarify the first model, the change in affinity to proteins may be responsible 
for the second.     
1.2. p53 R249S Hot-spot Mutation and Hepatocellular Carcinoma 
     Hepatocellular carcinoma (HCC) is the most common liver cancer [30], accounting for an 
estimated 600 000 deaths annually [31]. Moreover, HCC is one of the most widespread 
malignancies worldwide [32], standing among the five leading causes of cancer death in the 
world [30]. Chronic infections with hepatitis B or C virus and consumption of dietary 
aflatoxin B1 (AFB1) or alcohol are recognized as the foremost risk factors [32] [Fig. 1.7].  
 
Figure 1.7: Multistage hepatocarcinogenesis. (Hussain SP et al, 2007) [32] 
     From clinical perspective, local surgical resection or liver transplantation constitute the 
only “curative treatment” [30] [33] for HCC patients. The fact that majority of patients have 
 9
already widespread HCC tumors at the time of diagnosis further complicates their surgery 
[30]. Moreover, recurrence is observed in the half of patients with localized HCC tumors 
who undergo surgical treatment [30]. Such a severity of HCC, inefficiency of treatment 
methods, and the absence of effective diagnostic markers have turned this disease into one of 
the most critical and challenging areas in cancer biology [31] [33].    
     The molecular pathogenesis of HCC, which involves multiple genetic and epigenetic 
changes, still remains largely unknown [32] [31] [34]. Current understanding of 
hepatocarcinogenesis identifies it as a multistage process accompanied by accumulation of 
abundant genetic alterations, like the mutation in p53 [32] [35] [Fig. 1.7]. Aflatoxin B1 
(AFB1) plays a causative role in the process of hepatocarcinogenesis as a major chemical 
carcinogen [35] [32].   
Table 1.1: Hypothesis: dietary AFB1 exposure can cause 249ser (AGG-AGT) TP53 mutations during human 
liver carcinogenesis. (Staib et al., 2003 and Hussain SP et al., 2007) [32] 
    
     AFB1 is a very potential mutagen inducing a hot-spot p53 mutation [Fig. 1.3] in the third 
position of 249th codon [32] [35] [Table 1.1]. The resultant G→T transversion leads to the 
amino-acid substitution R249S (arginine to serine), which is extremely specific to HCC [35] 
[36]. Accordingly, this hot-spot mutation predominantly occurs in patients with 
hepatocellular tumors from the region of eastern Asia and sub-Saharan Africa, where the 
AFB1 dietary intake occurs as a common food contaminant [29] [32]. 
     Because of its remarkable specificity to HCC, R249S mutation is considered as one of the 
tumor-specific, ‘signature’ mutations of p53 [36]. This significant molecular link between the 
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exposure to a particular carcinogen and a specific type of cancer (as well as mutation) 
provides an elegant example of how environmental carcinogens can be implicated in the 
etiology of human cancers [32]. This remarkable correlation between AFB1 exposure and 
R249S p53 mutation can be due to at least two reasons [32]. While first explanation relies on 
the potential high mutability of the third base at 249th codon to AFB1, another one suggests 
that these R249S mutants may confer a unique growth and/or survival advantage to these 
liver cells, resulting in their selection in a tissue-specific manner [32]. 
1.3. Microarray-based Cancer Research and Bioinformatics 
     Performing global gene expression analysis became possible after development of 
expression microarrays [24]. Combined with advent of supporting bioinformatics tools, this 
innovation enabled for the first time a comprehensive analysis of cell transcriptome on 
genome wide-scale [24]. This high-throughput technology has been commonly exploited in a 
wide range of biological areas, such as study of cancer and neuroscience [37].     
     Defining molecular differences between cancerous and healthy cell is one of the major 
tasks in cancer biology [38]. Since microarray analysis enables tracking relative transcript 
levels during comparing different biological classes, it has proven to be invaluable in 
translational cancer research [39] [37]. Monitoring simultaneously the expression levels of 
numerous genes on an unbiased manner is promising to unravel the complicated gene-
expression programs governing tumorigenesis [33] [40].    
     The goal of bioinformatics is to develop and present software programs for the use of 
biologists as an applicable tool in solving complicated biological problems. Since microarray 
technology is highly dependent on bioinformatics and biostatistics, a                
comprehensive understanding of the large-scale data derived from array-based experiments 
highly demands application of the relevant computational tools [41].  
1.4. Gene Networks Analysis 
     It proved applicable to represent various biological datasets as “gene networks”, 
composed of multiple nodes (corresponding to genes or proteins) and connections (matching 
to physical interactions between these entities) [42]. In reality, these gene networks are a 
simplification of the ultimate biochemical network, which unequivocally includes all three 
interaction levels equivalent to three types of biological molecules (mRNA, proteins and 
metabolites) [43] [Fig. 1.8]. Therefore, network of interaction can be constructed on several 
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levels and can depict various interaction types [43]. But when the research is restrained to 
surveying gene expression, such as in microarray experiments, it’s appropriate to limit 
interaction network with the representative gene network to explain the data [43].  
     Regulatory system of cell is a complex mechanism, involving various cell signaling 
mechanisms and regulatory machinery [38] [44]. Many signaling molecules are implicated in 
this process as participants of complicated signal transduction processes, commonly referred 
as cell signaling pathways [38]. Since signaling pathways never occur in isolation in cell, but 
function as members of large biomolecular networks [43], it became clear that signaling 
takes place through a regulatory network of interacting signaling pathways [38]. On the other 
hand, it’s widely recognized that a coordinate response of a combination of genes is what 
responsible for most of the cellular behavior and phenotypes [43]. All these findings suggest 
that studying the complex architecture of signaling networks is thought to demonstrate how 
these complex biological traits arise and propagate [43] [38]. For the same reason, 
deciphering complicated regulatory program of cell through gene networks is a promising 
approach for combating complex diseases such as cancer [43]. 
 
Fig. 1.8: An example of a biochemical network. Molecular constituents (nodes of the network) are organized in 
three levels (spaces): mRNAs, proteins, and metabolites. Solid arrows indicate interactions, the signs of which 
(activation or repression) are not specified in this diagram. Projections of these interactions into the ‘gene 
space’, indicated by dashed lines, constitute a corresponding gene network. (Brazhnik P et al, 2002) [43]. 
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1.5. Integrated Analysis of Genomic Data 
     Microarray experiments currently stand as the major source for genomic high-throughput 
information [45]. Ultimate goal behind these experiments is to find out both differentially 
expressed genes and genes with similar expression pattern. The rationale of searching for 
similar expression patterns using clustering algorithms is that co-clustering genes are 
supposed to be functionally related to each other [43]. As a consequence, their products 
should preferentially interact with each other in order to execute common molecular 
functions [38]. From researchers’ perspective, since genes of interacting proteins are 
predisposed to share similar expression patterns, it’s reasonable to integrate both information 
sources in solving complex biological problems [45]. Indeed, linking the transcription pattern 
similarities of co-expressed genes to corresponding molecular interactions between their 
products has become one of the most appealing concepts of systems biology [45] [Fig. 1.9].  
 
Fig. 1.9: Overview of integrated analysis of genomic data. (Troyanskaya OG, 2005) [49] 
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     Applications have already demonstrated that analysis of the experimental data in the 
context of molecular interactions leads to better elucidation of interrelations among the 
discovered differentially expressed genes [46]. Progress of bioinformatics gave rise to 
numerous knowledge databases and computational tools that enable integrating massive 
high-throughput expression data with accumulating molecular interaction data into the united 
conceptual framework [47] [48] [49] [Fig. 1.9]. In conclusion, this integrative approach 
might provide valuable clues and lead to new ideas for comprehensive elucidation of 
multiple molecular mechanisms that govern cell behaviour.  
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CHAPTER 2: AIM AND APPROACH 
 
     Mutations in p53 are considered among the major cancer-causing genetic alterations in the 
process of carcinogenesis. In addition to loss of function of the p53 tumor suppressor, the 
resulting mutant p53 proteins contribute to the malignancies by enhancing tumorigenic 
properties of cells. Currently, the oncogenic properties of mutant p53 proteins still stand as 
an ill-known subject, and the mechanism responsible for this phenomenon remains to be 
uncovered. Investigating the role and the underlying mechanism of mutant p53 oncogenicity 
in the course of hepatocellular carcinoma (HCC) was the main objective of this thesis. p53 
mutation is one of the most carcinogenic steps in development of HCC, but overall impact of 
this mutation on the gene regulatory networks of liver cells is not well understood. Since we 
were interested in what effect this mutation has on development of HCC, p53 249th codon 
(AGG→AGT, arginine to serine) mutation, which is specific to HCC, was selected for our 
research. The specific aim of the present study was to find out the list of differentially 
expressed genes and the associated gene network affected by the expression of p53(R249S) 
mutant proteins.  
     Searching for genes that change expression in response to mutant p53 expression was a 
promising approach to unravel the mechanism underlying mutant p53 oncogenicity in HCC. 
Remarkably, it was the first time when genome-wide gene expression profiling was chosen 
as a means to discover a set of genes involved in this process. “Comparative genomic 
approach” using two isogenic HCC cell lines (HepG2 and its counterpart stably expressing 
p53(R249S) named HepG2-249.1) was selected as the experimental approach in our 
microarray experiment. Analysis of the raw data derived from this experiment constitutes 
first part of this study.  
     There were different approaches until now to elucidate the nature of mutant p53 
oncogenicity, most of which included gene expression analyses. However, this phenomenon 
has not been investigated yet in terms of gene networks, which confers additional originality 
to our approach. Mapping our significant differentially-expressed genes to the p53 interaction 
network and subsequent computational analysis of the resultant network represents second 
part of this study. It was strongly anticipated that interpretation of microarray data in context 
of diverse molecular interactions would lead to better elucidation of the interrelations among 
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the discovered differentially expressed genes and aid comprehensive cross-validation of our 
findings with the existing knowledge about the related molecular mechanisms.  
 
Figure 2.1: The workflow of the thesis. (Adopted from Affymetrix web site) [50] 
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1. Microarray Data Analysis 
3.1.1. Microarray Experiment     
     “Comparative genomic approach” using two isogenic HCC cell lines (HepG2 and its 
counterpart stably expressing codon 249 mutant p53 named HepG2-249.1) was exploited as a 
model for the microarray experiment. In order to achieve higher fidelity of the results, 
microarray analysis was performed using quadruplets of total RNA samples extracted from 
these cell lines. Affymetrix “HGU95Av2” Gene Chip (screening with 12.625 probe sets) [50] 
was exploited as the microarray platform of this expression analysis.  
3.1.2. Normalization of Raw Data      
     In silico analysis of acquired microarray data was made using R, which is a software 
environment for statistical computing and graphics. [51]. Quantile normalization [52] method 
was applied to normalize the raw expression data. 
3.1.3. Test of Differential Expression (Significance Testing)      
     We applied SAM (“Significance Analysis of Microarrays”), which is the most popular 
statistical method used for significance analysis [53], in order to test the differential 
expression and identify significant genes. SAMR package [54] for R was utilized for this 
purpose. 
3.1.4. Data Mining Using Functional Annotation Tools 
     Multiple annotation tools were used to interpret our microarray data results. NetAffx [55], 
WebGestalt [57], Onto-express [56] and Fatigo+ [58] were our top priority since these tools 
enable simultaneous input and analysis of multiple genes. List of our significant genes was 
given as an input for annotation analyses by these databases.  
3.1.5. Hierarchical Clustering      
     Gene expression patterns observed in microarray experiments can be interpreted as 
indications of the status of cellular processes and may provide a further insight to the 
coexpressed genes of unknown function [59]. Hierarchical clustering of significant genes 
according to their gene expressions was performed using Cluster [59] and Java Treeview [60] 
software. 
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3.2. Gene Network Analysis 
3.2.1. Mapping Significant Genes to Human BIND Network 
     Cytoscape [61] is open-source software for network visualization and analysis. 
Application of Cytoscape is most powerful when applied in combination with large databases 
of biomolecular interactions [61].  
     In order to analyse our findings on systems biology level, the list of significance genes 
was mapped onto BIND human protein interaction network [62] using Cytoscape software 
[61]. (BIND network is composed of experimentally proven biomolecular interactions 
(protein-protein and protein-DNA) [62]) Since we were interested in mutant p53 GOF, we 
also added p53 gene to the input list in order to discover the relationship between the 
significant genes and this gene. Consequently, the data set used for core network construction 
consisted of our significant genes, p53 and the molecules in the neighborhood. 
3.2.2. Integrating CXX1 and HNF4A to the Network 
     The resulting network was expanded by integrating CXX1 gene to the core network. 
Interaction data regarding CXX1 was retrieved from MINT database [63]. Moreover, 
additional direct interaction between HNF4A and p53 was adopted from String database [64] 
and added to the core network. 
3.2.3. Integrating Differential Expression with the Network 
     Cytoscape allows visual integration of biomolecular interaction networks with expression 
profiles derived from high-throughput expression data. Interactions of our resulting network 
were integrated with gene expression data obtained from microarray analysis. Visual Mapper 
feature of Cytoscape was used for this purpose, 
3.2.4. GO Annotation of the Network 
     The software “Core” of Cytoscape has been extensively extended through development of 
numerous plug-ins, allowing application of additional computational analyses and features 
[65]. Using such plug-ins may facilitate linking the network to databases of functional 
annotations.  
     Interactions of our resulting network were integrated with Gene Ontology (GO) 
Biological Process data [66] using GOlorize plug-in [67]. All nodes of the network were 
clustered and colored according to their corresponding GO category.  
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3.2.5. Alternative Layouts of the Network 
     Cerebral (Cell Region-Based Rendering And Layout) plug-in [68] for Cytoscape enables 
the visual integration of the network with subcellular localization data. This plug-in was used 
to generate an alternative layout of the interaction network according to the subcellular 
localization of the participating molecules. Related subcellular localization data was retrieved 
from Entrez Gene [8], UniProt [69] and MEP2SL [70] databases [Table A.4; Appendix]. 
Apart from this, the hierarchical layout of Cytoscape interface was used to determine 
hierarchical architecture of the network. 
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CHAPTER 4: RESULTS 
  
4.1. Microarray Data Analysis 
4.1.1. Microarray Experiment 
     Microarray experiment generated raw expression data, which was the starting point for the 
subsequent in silico analyses. 
4.1.2. Normalization of Raw Data 
     Raw expression data was normalized using Quantile normalization method [Fig. 4.1]. 
                            Before normalization                                               After normalization 
 
Figure 4.1: Normalization of raw expression values. 
4.1.3. Test of Differential Expression (Significance Testing) 
     Significance analysis of microarrays was used to identify significant probesets [Fig. 4.2]. 
Calculated delta table [Table A.1; Appendix] was used to generate the list of significant 
probesets and FDR equal to 0.049 was chosen as the significance level. As result 
differentially expressed 110 probesets (FDR<0.05) were selected for further analysis [Table 
A.2-3; Appendix]. 
                                                  SAMR plot                                Delta vs. Median false positives plot 
 
Figure 4.2: Significance Analysis of Microarrays. 
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4.1.4. Data Mining Using Functional Annotation Tools 
     Functional annotation of 110 significant probesets using NetAffx, WebGestalt and 
Babelomics databases showed that they correspond to 84 known genes (63 up- and 21 
downregulated) of various functions and properties [Table 4.1 and 4.2]. 
Table 4.1: List of upregulated significant genes. 
Order Symbol Gene Name   Fold Change 
1 CXX1 CAAX box 1 23.22800715
2 CD9 CD9 molecule 10.66870392
3 TRIB2 tribbles homolog 2 (Drosophila) 10.73610878
4 SPINK1 serine peptidase inhibitor, Kazal type 1 6.836368805
5 FGL1 fibrinogen-like 1 6.910175987
6 SCGN secretagogin, EF-hand calcium binding protein 7.394791124
7 TUBB2B tubulin, beta 2B 6.631740161
8 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 5.618615288
9 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 5.566360188
10 TRIB2 tribbles homolog 2 (Drosophila) 8.830691762
11 GAS7 growth arrest-specific 7 7.459127617
12 GPC3 glypican 3 4.385885356
13 CRIP1 cysteine-rich protein 1 (intestinal) 5.06460286
14 TFF3 trefoil factor 3 (intestinal) 5.646708948
15 CYP7A1 cytochrome P450, family 7, subfamily A, polypeptide 1 4.75273648
16 NT5E 5'-nucleotidase, ecto (CD73) 4.821628984
17 SEPT6 septin 6 3.892380553
18 IGFBP2 insulin-like growth factor binding protein 2, 36kDa 4.975579655
19 VTN vitronectin 3.497558863
20 ATP9A ATPase, Class II, type 9A 3.657102437
21 SALL1 sal-like 1 (Drosophila) 3.509610598
22 NFE2 nuclear factor (erythroid-derived 2), 45kDa 4.418474567
23 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 4.044187193
24 CDKL5 cyclin-dependent kinase-like 5 3.056986098
25 CD24 CD24 molecule 3.528537463
26 EMP2 epithelial membrane protein 2 3.292796742
27 DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) 3.680506015
28 TIMP2 TIMP metallopeptidase inhibitor 2 3.791424047
29 IGSF4 immunoglobulin superfamily, member 4 3.126117522
30 DPH4 DPH4 homolog (JJJ3, S. cerevisiae) 3.145138992
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31 DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) 2.814455399
32 RASSF2 Ras association (RalGDS/AF-6) domain family 2 3.483605186
33 CAMK2G calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma 3.20015185
34 MYO10 myosin X 6.26521794
35 GNMT glycine N-methyltransferase 2.833020285
36 PLA2G1B phospholipase A2, group IB (pancreas) 2.674845104
37 PDGFA platelet-derived growth factor alpha polypeptide 4.366942565
38 LY6E lymphocyte antigen 6 complex, locus E 2.812146331
39 ZNF185 zinc finger protein 185 (LIM domain) 3.302367067
40 ICAM2 intercellular adhesion molecule 2 3.290637749
41 GC group-specific component (vitamin D binding protein) 3.457322198
42 ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 2.574092795
43 OPHN1 oligophrenin 1 2.67282291
44 COMP cartilage oligomeric matrix protein 3.24477113
45 AFM afamin 4.403802207
46 FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 3.699118026
47 KNG1 kininogen 1 3.280106829
48 SP110 SP110 nuclear body protein 3.236990624
49 PGC progastricsin (pepsinogen C) 2.410266847
50 ARMC8 armadillo repeat containing 8 2.645574822
51 SH3BGRL SH3 domain binding glutamic acid-rich protein like 3.178723258
52 CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 2.447360881
53 LRP3 low density lipoprotein receptor-related protein 3 4.569480394
54 ALDH3A1 aldehyde dehydrogenase 3 family, memberA1 2.987214461
55 TSPAN7 tetraspanin 7 2.315269713
56 AADAC arylacetamide deacetylase (esterase) 2.531105015
57 CTSL2 cathepsin L2 3.491246648
58 PBXIP1 pre-B-cell leukemia transcription factor interacting protein 1 2.562377452
59 TNNI3 troponin I type 3 (cardiac) 3.109776838
60 FGA fibrinogen alpha chain 2.486721324
61 RBP1 retinol binding protein 1, cellular 3.438083597
62 FRK fyn-related kinase 3.62128114
63 PHYH phytanoyl-CoA 2-hydroxylase 2.503697831
64 PVRL3 poliovirus receptor-related 3 2.363370451
65 AGTR1 angiotensin II receptor, type 1 2.97706393
66 KIAA0649 KIAA0649 2.935727094
67 TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 2.840251507
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Table 4.2: List of downregulated significant genes. 
Order Symbol Gene Name   Fold Change 
1 MYL9 myosin, light chain 9, regulatory 0.06911942
2 PLP2 proteolipid protein 2 (colonic epithelium-enriched) 0.12872334
3 PRAME preferentially expressed antigen in melanoma 0.15274071
4 PLA2G2A phospholipase A2, group IIA (platelets, synovial fluid) 0.16698822
5 GLT25D2 glycosyltransferase 25 domain containing 2 0.16702497
6 APOL1 apolipoprotein L, 1 0.18826925
7 PLA2G2A phospholipase A2, group IIA (platelets, synovial fluid) 0.19549314
8 MFNG manic fringe homolog (Drosophila) 0.20099952
9 DLK1 delta-like 1 homolog (Drosophila) 0.2233338
10 CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 0.17863134
11 CPVL carboxypeptidase, vitellogenic-like 0.2460938
12 ASNS asparagine synthetase 0.24480766
13 ECGF1 endothelial cell growth factor 1 (platelet-derived) 0.24343787
14 ENPP2 ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) 0.27102712
15 ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 0.24614508
16 CD22 CD22 molecule 0.27344226
17 ABLIM3 actin binding LIM protein family, member 3 0.32283383
18 EREG epiregulin 0.26010424
19 IL18 interleukin 18 (interferon-gamma-inducing factor) 0.25988872
20 BICC1 bicaudal C homolog 1 (Drosophila) 0.30711096
21 MCC mutated in colorectal cancers 0.28560867
22 MCC mutated in colorectal cancers 0.34042488
23 TNFSF4 
tumor necrosis factor (ligand) superfamily, member 4 (tax-transcriptionally 
activated glycoprotein 1, 34kDa) 0.29873043
 
It was remarkable that 78 out of 84 significant genes were specific to liver which could be 
due to the anticipated tissue specificity of p53 R249S mutation to HCC [Fig. 4.3].  
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Figure 4.3: Bar chart of the tissue expression pattern. Each tissue is represented by a bar in the chart. The height 
of the bar represents the number of genes that are expressed in the tissue (from WebGestalt). 
     Significant genes were equally distributed in terms of chromosomal location. 
 
Figure 4.4: Chromosome distribution chart. Each chromosome is represented by a bar in the chart. Each gene is 
represented by a red cross symbol and located on the chromosome based on its location (from WebGestalt). 
     Classification of our significant genes according to molecular function demonstrated a 
noticeable high prevalence of “binding proteins” among them [Fig. 4.5 and 4.8]. This finding 
may reflect the possible role of these proteins in a signal transduction resulting from mutant 
p53 expression.   
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Figure 4.5: GO Molecular Function distribution chart (from Fatigo +). 
 
 
Figure 4.6: GO Biological Process distribution chart (from Fatigo +). 
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Figure 4.7: GO Cellular Component distribution chart (from Fatigo +). 
 
Figure 4.8: GO Molecular Function distribution flat pie chart (from Onto-express). 
 
 
Figure 4.9: GO Biological Function distribution flat pie chart (from Onto-express). 
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Figure 4.10: GO Cellular Component distribution flat pie chart (from Onto-express). 
4.1.5. Hierarchical Clustering 
     Hierarchical clustering of significant genes according to their gene expressions was 
demonstrated using Dendogram (Tree view) image of clustering genes. This analysis 
revealed that the expression of our significant genes was significantly correlated with p53 
status [Fig. 4.11]. 
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Figure 4.11: Dendogram demonstrating hierarchical clustering of significant genes. 
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4.2. Gene Network Analysis 
4.2.1. Mapping Significant Genes to Human BIND Network 
     22 of the genes given in the input were observed to be tightly related to each other and to 
TP53 with specific DNA-DNA or DNA-protein interactions, thus forming a putative 
interaction network with TP53 at the centre. While remaining genes were discarded, the 
genes contributing to the network were selected for future analysis.  
Table 4.3: Schematic representation of gene network analysis. 
 
 
4.2.2. Integrating CXX1 and HNF4A to the Network 
     The resulting network was expanded by integrating CXX1 gene to the core network. 
Moreover, additional direct interaction between HNF4A and p53 was also included in the 
core network [Fig. 4.12]. 
4.2.3. Integrating Differential Expression with the Network 
     Our resulting network data was integrated with corresponding gene expression data. 
Significant genes were colored according to their expression changes [Fig. 4.12].  
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Figure 4.12: Putative interaction network showing relationship between p53 and our significant genes.  
Visual style (the legend) of the network graphics is as below: 
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4.2.4. GO Annotation of the Network 
     Interactions of the resulting network were integrated with GO Biological Process data 
using GOlorize plug-in. All nodes of the network were clustered and colored according to 
their corresponding GO category. GO annotation of the obtained interaction network showed 
that the network was highly enriched with genes involved in cancer-related biological 
processes such as apoptosis, cell cycle, cell communication, and regulation of angiogenesis. 
Furthermore, the network was found to be overrepresented with the genes playing role in 
development and regulation of nucleobase metabolism [Fig. 4.13]. 
 
Figure 4.13: GO annotation of the network. 
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4.2.5. Alternative Layouts of the Network 
     Cerebral plug-in for Cytoscape was used to generate a layout of the network based on the 
subcellular localization of the participating molecules. This analysis revealed the distribution 
pattern of significant genes across the network. Noticeably, most of the direct neighbors of 
p53 were localized to nucleus and/or cytoplasm. The localization and interactions of HNF 
transcription factors in nucleus were also apparent [Fig. 1.14].  
 
Figure 4.14: Subcellular localization layout of the network. 
In addition, Hierarchical layout was used to determine the hierarchy of the network. This 
alternative layout of the network clearly demonstrated the significance and centrality of both 
p53 and HNF4A in the network [Fig. 1.15]. 
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Figure 4.15: Hierarchical layout of the network. 
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CHAPTER 5: DISCUSSION 
 
5.1. Discussion of the Results from Microarray Data Analysis 
     Microarray data analysis revealed a molecular signature consisting of 84 differentially 
regulated genes that could be segregated into two clusters of transcripts induced (n=63) and 
repressed (n=21) by mutant p53 expression [Table 4.1-4.2]. 
     Since quantitative value sets gained from microarray data don’t necessarily answer the 
research question, translation of this expression data to biologically meaningful information, 
known as data mining, is achieved using functional annotation tools which enable further 
analysis of significant genes for biological significance in the light of all the existing 
knowledge. Functional annotation tools helped us to accurately interpret our microarray data 
by analyzing our microarray results in the context of other biological information.  
Annotation showed that the translated proteins of our significant genes possessed diverse 
properties and were involved in various processes [Fig. 4.3-4.10].  
     To our surprise, for the most of our significant genes, there was no solid evidence in 
literature and databases about their functional involvement in cancer. Since molecular basis 
of mutant p53(R249S) oncogenicity is a poorly-known, these genes may constitute to a novel 
mechanism responsible for this process, and thus contribute to tumorigenesis.       
     Classification of our significant genes according to molecular function demonstrated a 
noticeable high prevalence of “binding proteins” among them [Fig. 4.5 and 4.8]. This finding 
may reflect the possible role of these proteins in a signal transduction resulting from mutant 
p53 expression.   
     It was remarkable that 78 out of 84 significant genes were specific to liver which could be 
due to the anticipated tissue specificity of p53 R249S mutation to HCC [Fig. 4.3].  
     Hierarchical clustering of significant genes according to their gene expressions revealed 
that the expression of our significant genes was significantly correlated with p53 status [Fig. 
4.11].  
     Interestingly, CXX1 (CAAX box protein 1) was the most extraordinary and prominent 
differentially expressed transcript among our significant genes. Besides being the most 
overexpressed one, very little is known about its translated protein, which makes this gene 
one of our target candidate genes for further study. This putatively prenylated protein of 
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unknown function is ubiquitously expressed in tissues and localized to cell membrane in cells 
[69]. In our interaction network, CXX1 was found to be in interaction with HBP1 (HMG-box 
transcription factor 1), which is a transcription factor playing a role in the regulation of the 
cell cycle [69] [71] [Fig. 4.12].  One significant finding is that HBP1 maintains a 
proliferation barrier in differentiated liver tissue [72]. Noticeably, HBP1 is also a common 
transcriptional target of HNF4A and HNF6 transcription factors, which are highly functional 
in liver [73] [Fig. 4.12]. Taken together, this intriguing background makes CXX1, together 
with HBP1, worth further investigation for elucidation of their potential role in HCC.    
     Among our significant genes, Insulin-like growth factor-binding protein-2 (IGFBP2) and 
glypican-3 (GPC3) were proposed by earlier studies to be valuable as potential diagnostic 
biomarkers of HCC [74] [75]. Consistent with that, both of these genes were found to be 
significantly overexpressed in our microarray experiment.   
     Finally, it was remarkable that two components of fibrinogen complex (FGL1 and FGA) 
mapped p53 network as the significantly overexpressed genes. Interestingly, they were both 
possessing molecular function annotated as “cell communication”. This could be 
representing a novel type of signalling mediated by fibrinogen components and contributing 
to mutant p53(R249S) oncogenicity in HCC. 
     Validation of significant genes by both semi-quantitative and real-time RT-PCR is among 
our future goals. Furthermore, we aim to use a list of different cell lines in order to 
demonstrate that differential expression of our significant genes is not cell line specific but 
rather a common feature. 
5.2. Discussion of the Results from Gene Network Analysis 
     Comprehensive network analysis of significant genes using Cytoscape and additional 
plug-ins provided a further insight into the investigated molecular mechanism. To our 
surprise, significant genes had no interaction between them, but were in close relation with 
direct neighbours of p53. This resulted in accumulation of significant genes around p53 
molecule in our network, clearly demonstrating their relationship to p53 [Fig. 4.12]. This was 
highly in concordance with our expectations since we were anticipating this relationship 
between our significant genes and p53. GO annotation of the obtained interaction network 
showed that the network was highly enriched with genes involved in cancer-related 
biological processes such as apoptosis, cell cycle, cell communication and angiogenesis [Fig. 
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4.13]. Noticeably, interacting genes were usually sharing the same GO category, which 
clearly demonstrates the significance of interactions in understanding gene function [Fig. 
4.13]. On the other hand, an alternative layout generated by Cerebral plug-in demonstrated 
the distribution of molecules involved in the network according to their subcellular 
localization. Our significant genes, together with neighbor molecules, were found to be 
equally distributed throughout the cell [Fig. 4.14]. 
     Taking in account that most of our significant genes in the network were the direct 
transcriptional downstream targets of HNF transcription factors, the functional relationship 
between HNF factors and mutant p53 oncogenicity in HCC becomes apparent [Fig. 4.12]. 
Hierarchical layout of Cytoscape interface, used to obtain an alternative image of the 
network, clearly demonstrated the significance and centrality of both p53 and HNF4A in the 
network [Fig. 4.15].   
     It’s widely recognized by the scientific community that the transcription factors HNF1A, 
HNF4A and HNF6, which function coordinately in a connected network in hepatocytes, 
regulate the development and function of liver, [73] [76] [Fig. 5.1].  
 
Figure 5.1: Control of liver gene expression by HNF transcription factors. A. Interactions among HNFs in a 
hepatocyte. B. HNF1A, HNF6, and HNF4A are at the center of tissue-specific transcriptional regulatory 
networks. In these examples selected for illustration, regulatory proteins and their gene targets are represented 
as blue circles and red boxes, respectively. Solid arrows indicate protein-DNA interactions, and genes encoding 
regulators are linked to their protein products by dashed lines. (Kulkarni RN and Kahn CR, 2004; Odom DT et 
al., 2004) [73] [76].                                                                         
     Interestingly, genome-scale chromatin immunoprecipitation (ChIP) assays performed by 
Odom DT and his colleagues revealed that the number of genes transcriptionally regulated by 
HNF4A in hepatocytes was much larger than observed with other transcription factors [73]. 
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The observation that HNF4A is binding to an unusual large number (almost half) of active 
promoters suggests that HNF4A has a broad activity in liver and explains why HNF4A is so 
crucial in development and activity of this organ [73] [76]. This observation is also in 
consistence with our results obtained from network analysis, since most of our differentially 
regulated significant genes were found to be interacting partners and transcriptional targets of 
HNF4A [Fig. 4.12 and 4.15]. 
     Evidence from the literature that wild-type p53 can bind to HNF4A protein and inhibit its 
transcriptional function is shedding some light on our findings [77] [Fig 4.12]. Since this 
repression of HNF4A has been shown with wild-type form of p53, it is difficult to speculate 
about the relation of this repression with mutant forms. But when this observation is 
interpreted in the light of our findings, especially those coming from the network analysis, it 
is possible to drive an appropriate conclusion about the role of HNF4A in mutant p53 
oncogenicity in HCC. According to one of the models describing mutant p53 transcriptional 
activity, mutant p53 interacts with a specific transcription factor that drives its gene target 
specificity by recruiting it to target genes’ promoters [Fig. 1.5]. Consistent with this, our 
findings strongly suggests that mutant p53 interacts with HNF4A in order to achieve 
transcriptional regulation of its target genes (which correspond to our significant genes) and 
promote its oncogenic effect in HCC. Specificity of both HNF4A transcription factors and 
p53 R249S mutant proteins to HCC, further increases significance of this hypothesis and 
emphasizes the tissue specificity of these molecular mechanisms to HCC. We aim to perform 
a series of biochemical analysis to test the proposed functional relationship between HNFA 
and p53 R249S mutant proteins.  
5.3. Conclusion and Future Perspectives 
     The aim of the present study was to find out the list of differentially expressed genes and 
the associated gene network affected by the expression of p53(R249S) mutant proteins. 
Searching for genes that change expression in response to p53 mutation may provide a clue 
to the mechanism underlying mutant p53 oncogenicity in HCC. Thus, genome-wide gene 
expression profiling was used to discover a set of genes involved in this process. 
“Comparative genomic approach” using two isogenic HCC cell lines was exploited as a 
model for our microarray experiment.  
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     Microarray data analysis revealed a molecular signature consisting of 84 differentially 
regulated genes (FDR<0.05) that could be segregated into two clusters of transcripts induced 
(n=63) and repressed (n=21) by mutant p53 expression, showing that the expression of 
mutant p53 proteins resulted in overall distinct expression profile.  
     Analyzing our microarray data in the light of the relevant biological data obtained from 
the curated databases (such as annotation and interaction data) provided a more reliable 
interpretation of our experimental findings, which led to more comprehensive understanding 
of the investigated molecular mechanisms. Functional annotation and network analysis 
resulted in a better elucidation of the interrelations among the discovered differentially 
expressed genes and aided comprehensive cross-validation of our findings with the existing 
knowledge about the related molecular mechanisms. We demonstrated that several 
Hepatocyte Nuclear Factors (HNF1A, HNF4A and HF6) could play an essential role in 
mediating mutant p53 oncogenic activity, as the key molecules of the gene network. 
Deregulation of the transcriptional control mediated by these transcription factors appears to 
be the major mechanism underlying mutant p53 oncogenicity in HCC. Remarkably, CXX1, 
which is a gene of unknown function, was prominent as the most upregulated transcript 
among our differentially expressed genes. Further functional analysis of these and other 
candidate genes of the gene network shall clarify their potential relation to mutant p53 and 
elucidate their presumptive contribution to the development of HCC.   
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APPENDIX 
 
Table A.1: Delta table. 
         delta     # med false pos      90th perc false pos  # called   median FDR   90th perc FDR 
0 8911.524277 9046.506931 11957 0.74529767 0.75658668 
0.000470238 8882.163644 9025.153743 11926 0.74477307 0.756762849 
0.001880953 8815.053624 8962.619406 11864 0.74300857 0.75544668 
0.004232143 8688.078416 8853.565624 11755 0.73909642 0.753174447 
0.007523811 8518.778139 8714.388594 11603 0.73418755 0.75104616 
0.011755954 8317.066772 8543.563089 11431 0.72758873 0.747402947 
0.016928574 7703.162614 8065.404198 10853 0.70977265 0.743149746 
0.02304167 6991.262574 7488.105505 10170 0.68743978 0.73629356 
0.030095242 6132.559366 6790.695129 9305 0.65906065 0.729789912 
0.038089291 5220.854495 6034.563485 8349 0.62532692 0.722788775 
0.047023816 4419.347327 5333.34004 7508 0.58861845 0.710354294 
0.056898817 3601.44396 4599.324198 6626 0.54353214 0.69413284 
0.067714295 2719.862337 3738.333149 5519 0.49281796 0.677356976 
0.079470249 1875.648792 2848.362772 4339 0.43227674 0.656456043 
0.092166679 1348.301307 2236.746455 3503 0.38489903 0.63852311 
0.105803585 920.4749307 1675.84396 2704 0.34041233 0.619764778 
0.120380968 640.2143366 1257.550257 2117 0.30241584 0.594024685 
0.135898827 415.2432475 885.3946931 1543 0.26911422 0.5738138 
0.152357163 271.8718416 626.1059802 1141 0.23827506 0.548734426 
0.169755975 162.4367525 416.0058614 775 0.20959581 0.536781757 
0.188095263 113.2481584 301.9950891 601 0.18843288 0.502487669 
0.207375027 64.44087129 196.7543762 414 0.15565428 0.475252117 
0.227595268 38.512 142.990099 317 0.12148896 0.451072868 
0.248755985 25.92887129 109.0537822 249 0.10413201 0.437966997 
0.270857178 13.7270495 72.82962376 167 0.0821979 0.436105532 
0.293898848 7.626138614 55.67081188 138 0.05526187 0.40341168 
0.317880994 5.33829703 41.18114851 110 0.04852997 0.374374077 
0.342803616 2.287841584 29.74194059 86 0.02660281 0.345836519 
0.368666715 1.906534653 24.7849505 79 0.02413335 0.313733551 
0.39547029 1.143920792 20.20926733 69 0.01657856 0.292887932 
0.423214341 0.762613861 15.63358416 42 0.01815747 0.372228194 
0.451898869 0 13.34574257 36 0 0.370715072 
0.481523873 0 12.58312871 34 0 0.370092021 
0.512089353 0 10.67659406 30 0 0.355886469 
0.543595309 0 10.29528713 29 0 0.355009901 
0.576041742 0 9.913980198 28 0 0.354070721 
0.609428651 0 8.388752475 27 0 0.310694536 
0.643756037 0 7.626138614 24 0 0.317755776 
0.679023899 0 6.100910891 18 0 0.338939494 
0.715232237 0 3.050455446 10 0 0.305045545 
0.752381051 0 2.287841584 9 0 0.25420462 
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0.790470342 0 2.287841584 8 0 0.285980198 
0.829500109 0 0.381306931 4 0 0.095326733 
0.869470352 0 0.381306931 3 0 0.12710231 
0.910381072 0 0 2 0 0 
0.952232268 0 0 2 0 0 
 
Table A.2: Upregulated significant probesets. 
  Order Affy ID              Fold Change       Order Affy ID          Fold Change 
1 33856_at 23.22800715 44 35540_at 3.6593011 
2 39389_at 10.66870392 45 35599_at 2.8330203 
3 717_at 10.73610878 46 912_s_at 2.6748451 
4 38582_at 6.836368805 47 35703_at 4.3669426 
5 40567_at 10.78087903 48 37360_at 2.8121463 
6 41416_at 6.910175987 49 37538_at 3.8505759 
7 37478_at 7.394791124 50 32139_at 3.3023671 
8 39332_at 6.631740161 51 38454_g_at 3.2906377 
9 1741_s_at 5.618615288 52 32771_at 3.4573222 
10 38396_at 5.099639465 53 41352_at 2.5740928 
11 2053_at 5.566360188 54 1089_i_at 11.995563 
12 40113_at 8.830691762 55 39413_at 2.6728229 
13 33387_at 7.459127617 56 39959_at 3.1956445 
14 39350_at 4.385885356 57 40162_s_at 3.2447711 
15 33232_at 5.06460286 58 33564_at 4.4038022 
16 31477_at 5.646708948 59 444_g_at 2.4560301 
17 31926_at 4.75273648 60 41628_at 3.699118 
18 31886_at 4.821628984 61 37235_g_at 3.2801068 
19 38826_at 3.892380553 62 35718_at 3.2369906 
20 40422_at 4.975579655 63 33699_at 2.4102668 
21 33377_at 3.497558863 64 443_at 2.9843342 
22 35831_at 3.657102437 65 38645_at 2.6455748 
23 32985_at 3.509610598 66 39714_at 3.1787233 
24 37179_at 4.418474567 67 33113_at 2.4473609 
25 36757_at 4.224963097 68 31814_i_at 4.5694804 
26 35127_at 4.062052119 69 40031_at 2.9872145 
27 2054_g_at 4.044187193 70 38408_at 2.3152697 
28 36707_s_at 3.056986098 71 36512_at 2.531105 
29 266_s_at 3.528537463 72 37203_at 2.7636325 
30 39631_at 3.292796742 73 38576_at 3.2969438 
31 33408_at 3.680506015 74 40717_at 3.4912466 
32 1375_s_at 3.791424047 75 38063_at 2.5623775 
33 37929_at 3.126117522 76 36477_at 3.1097768 
34 38294_at 3.09622336 77 35829_at 2.3612818 
35 39282_at 3.145138992 78 38825_at 2.4867213 
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36 1090_f_at 4.446741526 79 38634_at 3.4380836 
37 32609_at 3.880073136 80 35023_at 3.6212811 
38 33407_at 2.814455399 81 32724_at 2.5036978 
39 36727_at 4.36872055 82 34202_at 2.3633705 
40 37598_at 3.483605186 83 37983_at 2.9770639 
41 36983_f_at 3.15185107 84 39580_at 2.9357271 
42 32105_f_at 3.20015185 85 1715_at 2.8402515 
43 35362_at 6.26521794    
 
Table A.3: Downregulated significant probesets. 
Order Affy ID       Fold Change 
1 39145_at 0.069119421 
2 37326_at 0.128723343 
3 33541_s_at 0.136525709 
4 157_at 0.15274071 
5 37017_at 0.166988218 
6 39550_at 0.167024973 
7 35099_at 0.188269253 
8 614_at 0.195493145 
9 41522_at 0.200999525 
10 32648_at 0.223333805 
11 660_at 0.17863134 
12 38323_at 0.246093797 
13 39470_at 0.254135678 
14 36671_at 0.244807658 
15 1665_s_at 0.243437875 
16 41123_s_at 0.271027122 
17 34256_at 0.246145082 
18 38522_s_at 0.273442262 
19 39597_at 0.322833829 
20 34476_r_at 0.260104239 
21 1165_at 0.25988872 
22 39506_at 0.307110964 
23 35561_at 0.285608674 
24 1832_at 0.340424877 
25 32319_at 0.298730427 
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Table A.4: Input data of subcellular localization labels for Cerebral plug-in. 
Localization 
Fibrinogen_Beta_Chain = Secreted protein 
Ca2+ = Secreted protein 
OAP = Unknown 
NFKBIB = Secreted protein 
Fibrin_Gamma_Chain = Secreted protein  
PRAME = Cytoplasm/Nucleus 
HNF6 = Nucleus 
BHP = Unknown 
ITGA3 = Cell membrane 
BARD1 = Cytoplasm/Nucleus 
HNF4-alpha =Nucleus 
PPP1CA = Cytoplasm 
EP300 = Nucleus 
SPINK1 = Secreted protein 
Fibrin = Secreted protein 
XRCC6 = Nucleus 
ITGB1 = Cell membrane 
PLA2G2A = Cell membrane 
STK19 = Nucleus 
SUMO-1 = Cytoplasm/Nucleus 
TNNC1 = Cytoplasm 
EPB41L3 = Cell membrane 
CD9 = Cell membrane 
Htt = Cell membrane 
GEL = Cytoplasm/Nucleus 
AGTR1 = Cell membrane 
FRK = Cytoplasm 
ITGA5 = Cell membrane 
SALL1 = Nucleus 
TNNT2 = Cytoplasm 
AADAC = Cytoplasm 
Fibrin_Beta_Chain = Secreted protein 
CD_155 = Cell membrane 
SH3BGRL = Cytoplasm/Nucleus 
TIMP2 = Secreted protein 
INB = Unknown 
FGA = Secreted protein 
CXX1 = Cell membrane 
NAG-(4-1)NAG = Unknown 
Fibrinogen = Secreted protein 
MMP14 = Cell membrane 
CITED2 = Nucleus 
TNFRSF10B = Cell membrane 
Fibrinogen_Gamma_Chain = Secreted protein 
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IEX-1 = Cell membrane 
Zn2+ = Cytoplasm/Nucleus 
HNF1-alpha = Nucleus 
ITGA2 = Cell membrane 
KIAA0649 = Cytoplasm/Nucleus 
UBE2I = Nucleus 
ALDH3A1 = Cytoplasm 
TNFSF10 = Cell membrane 
FGL1 = Secreted protein 
BAT2 = Cytoplasm/Nucleus 
MMP2 = Secreted protein 
GNMT = Cytoplasm 
NAG = Cytoplasm/Nucleus 
LY6E = Cell membrane 
HBP1 = Nucleus 
MCC = Cytoplasm/Nucleus 
VTN = Secreted protein 
TP53 = Cytoplasm/Nucleus 
TNNI3 = Cytoplasm 
 
 
 
